Delivery of protein and peptide drugs to brain tumors

Delivery of Protein and Peptide Drugs in Cancer

Volumn , Issue , 2006, Pages 309-334

  Newton, Herbert B ^a  

^a OHIO STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 34447628400     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1142/9781860948039_0014     Document Type: Chapter

References (97)

1. Newton HB (1994) Primary brain tumors: Review of etiology, diagnosis, and treatment. Am Fam Phys 49:787-797.
2. Davis FG and McCarthy BJ (2001) Current epidemiological trends and surveillance issues in brain tumors. Exp Rev Anticancer Ther 1:395-401.
3. Wrensch M, Minn Y, Chew T, Bondy M and Berger MS (2002) Epidemiology of primary brain tumors: Current concepts and review of the literature. Neuro Oncol 4:278-299.
4. Kleihues P, Louis DN, Scheithauer BW and et al. (2002) The WHO classification of tumors of the nervous system. J Neuropathol Exp Neurol 61:215-225.
5. Newton HB (1999) Neurological complications of systemic cancer. Am Fam Phys 59:878-886.
6. Legler JM, Ries LA, Smith MA and et al. (1999) Cancer surveillance series [corrected]: Brain and other central nervous system cancers: Recent trends in incidence and mortality. J Natl Cancer Inst 91:1382-1390.
7. ACS (American Cancer Society): Cancer facts and figures 2002. American Cancer Society: Atlanta. 2002.
8. Fine HA, Dear KBG, Loeffler JS, Black PM, Canellos GP (1993) Meta-analysis of radiation therapy with and without adjuvant chemotherapy for malignant gliomas in adults. Cancer 71:2585-2597.
9. Stewart LA, Burdett S, Parmar MKB and et al. (2002) Chemotherapy in adult high-grade glioma: A systematic review and meta-analysis of individual patient data from 12 randomized trials. Lancet 359:1011-1018.
10. Newton HB (2003) Molecular neuro-oncology and the development of “targeted” therapeutic strategies for brain tumors. Part 1 - growth factor and ras signaling pathways. Exp Rev Anticancer Ther 3:595-614.
11. Newton HB (2004) Molecular neuro-oncology and the development of “targeted” therapeutic strategies for brain tumors. Part 2-PI3K/Akt/PTEN, m TOR, SHH/PTCH, and angiogenesis. Exp Rev Anticancer Ther 4:105-128.
12. Newton HB (2004) Molecular neuro-oncology and the development of “targeted” therapeutic strategies for brain tumors. Part 3-brain tumor invasiveness. Exp Rev Anticancer Ther 4:803-821.
13. Newton HB (2005) Molecular neuro-oncology and the development of “targeted” therapeutic strategies for brain tumors. Part 4-p53 signaling pathways. Exp Rev Anticancer Ther 5:177-191.
14. Newton HB (2005) Molecular neuro-oncology and the development of “targeted” therapeutic strategies for brain tumors. Part 5 - apoptosis and cell cycle. Exp Rev Anticancer Ther 5:355-378.
15. Pardridge WM (1999) Blood-brain barrier biology and methodology. J Neurovirol 5:556-569.
16. Pardridge WM (2005) Molecular biology of the blood-brain barrier. Mol Biotechnol 30:57-70.
17. Shusta EV (2005) Blood-brain barrier genomics, proteomics, and new transporter discovery. NeuroRx 2:151-161.
18. Tsuji A and Tamai II (1999) Carrier-mediated or specialized transport of drugs across the blood-brain barrier. Adv Drug Deliv Rev 36:277-290.
19. de Boer AG, van der Sandt ICJ and Gaillard PJ (2003) The role of drug transporters at the blood-brain barrier. Ann Rev Pharmacol Toxicol 43:629-656.
20. Borst P, Evers R, Kool M and Wijnholds J (2000) Afamily of drug transporters: The multidrug resistance-associated proteins. J Natl Cancer Inst 92:1295-1302.
21. Schlageterr KE, Molnar P, Lapin GD and Groothuis DR (1999) Microvesesel organization and structure in experimental brain tumors: Microvessel populations with distinctive structural and functional properties. Microvasc Res 58:213-328.
22. Groothuis DR (2000) The blood-brain and blood-tumor barriers: A review of strategies for increasing drug delivery. Neuro Oncol 2:45-59.
23. Parney IF and Prados MD (2005) Chemotherapy principles in Textbook of Neuro-Oncology, Vol. 11 Berger MS and Prados MD (eds.), Elsevier Saunders: Philadelphia, 75-79.
24. Pardridge WM (1998) CNS drug design based on principles of blood-brain barrier transport. J Neurochem 70:1781-1792.
25. Rapoport SI, Ohno K and Pettigrew KD (1979) Drug entry into the brain. Brain Res 172:354-359.
26. Levin VA (1980) Relationship of octanol/water partition coefficient and molecular weight to rat brain capillary permeability. J Med Chem 23:682-684.
27. Blasberg RG and Groothuis DR (1986) Chemotherapy of brain tumors: Physiological and pharmacokinetic considerations. Semin Oncol 13:70-82.
28. Diamond JM and Wright EM (1969) Molecular forces governing non-electrolyte permeation through cell membranes. Proc Royal Soc Lond [Biol] 172:273-316.
29. Jain RK (1987) Transport of molecules in the interstitium: A review. Cancer Res 47:3039-3051.
30. Stohrer M, Boucher Y, Stangassinger M and Jain RK (2000) Oncotic pressure in solid tumors is elevated. Cancer Res 60:4251-4255.
31. Abbott NJ and Romero IA (1996) Transporting therapeutics across the bloodbrain barrier. Mol Med Today March 106-113.
32. Kroll RA and Neuwelt EA (1998) Outwitting the blood-brain barrier for therapeutic purposes: Osmotic opening and other means. Neurosurg 42:1083-1100.
33. Pardridge WM (2001) Brain drug targeting and gene technologies. Jpn J Pharmacol 87:97-103.
34. Pardridge WM (2002) Drug and gene targeting to the brain with molecular Trojan horses. Nat Rev Drug Discov 1:131-139.
35. Pardridge WM (2002) Targeting Neurotherapeutic agents through the bloodbrain barrier. Arch Neurol 59:35-40.
36. Demeule M, Régina A, Annabi B, Bertrand Y, Bojanowski MW and Béleveau R (2004) Brain endothelial cells as pharmacological targets in brain tumors. Mol Neurobiol 30:157-183.
37. McCarty JH (2005) Cell biology of the neurovascular unit: implications for drug delivery across the blood-brain barrier. Assay Drugs Dev Technol 3:89-95.
38. Egleton RD and Davis TP (2005) Development of neuropeptide drugs that cross the blood-brain barrier. NeuroRx 2:44-53.
39. Tsuji A (2005) Small molecular drug transfer across the blood-brain barrier via carrier-mediated transport systems. NeuroRx 2:54-62.
40. Cucullo L, Aumayr B, Rapp E and Janigro D (2005) Drug delivery and in vitro models of the blood-brain barrier. Curr Opin Drug Discov Devel 8:89-99.
41. Chikhale EG, Ng KY, Burton PS and Borchardt RT (1994) Hydrogen bonding potential as a determinant of the in vitro and in situ blood-brain permeability of peptides. Pharm Res 11:412-419.
42. Poduslo JF and Curran GL (1994) Glycation increases the permeability of proteins across the blood-nerve and blood-brain barriers. Brain Res Mol Brain Res 23:157-162.
43. Egleton RD, Mitchell SA, Huber JD and et al. (2000) Improved bioavailability to the brain of glycosylated Met-enkephalin analogs. Brain Res 881:37-46.
44. Caliceti P and Veronese FM (2003) Pharmacokinetic and biodistribution properties of poly(ethyleneglycol)-protein conjugates. Adv Drug Deliv Rev 26:1261-1277.
45. Harris JM and Chess RB (2003) Effect of pegylation on pharmaceuticals. Nat Rev Drug Discov 2:214-221.
46. Morpurgo M and Veronese FM (2004) Conjugates of peptides and proteins to polyethylene glycols. Methods Mol Biol 283:45-70.
47. Pardridge WM, Wu D and Sakane T (1998) Combined use of carboxyl-directed protein pegylation and vector-mediated blood-brain barrier drug delivery system optimizes brain uptake of brain-derived neurotropic factor following intravenous administration. Pharm Res 15:576-582.
48. Molineux G (2003) Pegylation: Engineering improved biopharmaceuticals for oncology. Pharmacother 23:3S-8S.
49. Deguche Y, Kurihara A and Pardridge WM (1999) Retention of biologic activity of human epidermal growth factor following conjugation to a blood-brain barrier drug delivery vector via an extended poly(ethylene glycol) linker. Bioconjugate Chem 10:32-37.
50. Kreuter J (2001) Nanoparticulate systems for brain delivery of drugs. Adv Drug Del Rev 47:65-81.
51. Lockman PR, Mumper RJ, Khan MA and Allen DD (2002) Nanoparticle technology for drug delivery across the blood-brain barier. Drug Dev Ind Pharm 28:1-13.
52. Olivier JC (2005) Drug transport to brain with targeted nanoparticles. NeuroRx 2:108-119.
53. Gref R, Domb A, Quellec P and et al. (1995) The controlled intravenous delivery of drugs using PEG-coated sterically stabilized nanospheres. Adv Drug Deliv Rev 16:215-233.
54. Olivier JC, Huertas R, Lee HJ, Calon F and Pardridge WM (2002) Synthesis of pegylated immunonanoparticles. Pharm Res 19:1137-1143.
55. Gelperina SE, Khalansky AS, Skidan IN and et al. (2002) Toxicological studies of doxorubicin bound to polysorbate 80-coated poly(butyl cyanoacrylate) nanoparticles in healthy rats and rats with intracranial glioblastoma. Toxicol Lett 126:131-141.
56. Steininger SC, Kreuter J, Khalanskyi AS and et al. (2004) Chemotherapy of glioblastoma in rats using doxorubicin-loaded nanoparticles. Int J Cancer 109:759-767.
57. Koziara JM, Lockman PR, Allen DD and Mumper RJ (2004) Paclitaxel nanoparticles for the potential treatment of brain tumors. J Control Rel 99:259-269.
58. Brigger I, Morizet J, Laudani L and et al. (2004) Negative preclinical results with stealth nanospheres-encapsulated doxorubicin in an orthotopic murine brain tumor model. J Control Rel 100:29-40.
59. Di Paolo A (2004) Liposomal anticancer therapy: Pharmacokinetic and clinical aspects. J Chemother 16:90-93.
60. Fenske DB and Cullis PR (2005) Entrapment of small molecules and nucleic acid-based drugs in liposomes. Methods Enzymol 391:7-40.
61. Schnyder A and Huwyler J (2005) Drug transport to brain with targeted liposomes. NeuroRx 2:99-107.
62. Allen TM (1994) Long-circulating (sterically stabilized) liposomes for targeted drug delivery. Trends Pharmacol Sci 15:215-220.
63. Huwyler J, Wu D and Pardridge WM (1996) Brain drug delivery of small molecules using immunoliposomes. Proc Natl Acad Sci USA 93:14164-14169.
64. Zhang Y, Zhu C and Pardridge WM (2002) Antisense gene therapy of brain cancer with an artificial virus gene delivery system. Mol Ther 6:67-72.
65. Abraham SA, Waterhouse DN, Mayer LD, Cullis PR, Madden TD and Bally MB (2005) The liposomal formulation of doxorubicin. Meth Enzymol 391:71-97.
66. Allen TM and Martin FJ (2004) Advantages of liposomal delivery systems for anthracyclines. Sem Oncol 31:5-15.
67. Vail DM, Amantea MA, Colbern GT, Martin FJ, Hilger RA and Working PK (2004) Pegylated liposomal doxorubicin: proof of principle using preclinical animal models and pharmacokinetic studies. Sem Oncol 31:16-35.
68. Siegal T, Horowitz A and Gabizon A (1995) Doxorubicin encapsulated in sterically stabilized liposomes for the treatment of a brain tumor model: Biodistribution and therapeutic efficacy. J Neurosurg 83:1029-1037.
69. Sharma US, Sharma A, Chau RI and Straubinger RM (1997) Liposome-mediated therapy of intracranial brain tumors in a rat model. Pharm Res 14:992-998.
70. Saito R, Bringas JR, McKnight TR and et al. (2004) Distribution of liposomes into brain and rat brain tumor models by convection-enhanced delivery monitored with magnetic resonance imaging. Cancer Res 64:2572-2579.
71. Koukourakis MI, Koukouraki S, Fezoulidis I and et al. (2000) High intratumoral accumulation of stealth liposomal doxorubicin (Caelyx) in glioblastomas and in metastatic brain tumors. Br J Cancer 83:1281-1286.
72. Fabel K, Dietrich J, Hau P and et al. (2001) Long-term stabilization in patients with malignant glioma after treatment with liposomal doxorubicin. Cancer 92:1936-1942.
73. Hau P, Fabel K, Baumgart U and et al. (2004) Pegylated liposomal doxorubicinefficacy in patients with recurrent high-grade glioma. Cancer 100:1199-1207.
74. Chua SL, Rosenthal RA, Wong SS and et al. (2004) Phase 2 study of temozolomide and caelyx in patients with recurrent glioblastoma multiforme. Neuro-Oncol 6:38-43.
75. Bobo RH, Laske DW, Akbasak A, Morrison PF, Dedrick RL and Oldfield EH (1994) Convection-enhanced delivery of macromolecules in the brain. Proc Natl Acad Sci 91:2-76-2080.
76. Lieberman DM, Laske DW, Morrison PF, Bandiewicz KS and Oldfield EH (1995) Convection-enhanced distribution of large molecules in gray matter during interstitial drug infusion. J Neurosurg 82:1021-1029.
77. Mamot C, Nguyen JB, Pourdehnad M and et al. (2004) Extensive distribution of liposomes in rodent brains and brain tumors following convection-enhanced delivery. J Neuro Oncol 68:1-9.
78. Meredith RF and LoBuglio AF (1997) Recent progress in radioimmunotherapy of cancer. Oncol 11:979-987.
79. Kalofonos HP, Pawlikowska TR, Hemingway A and et al. (1989) Antibody guided diagnosis and therapy of brain gliomas using radiolabeled monoclonal antibodies against epidermal growth factor receptor and placental alkaline phosphatase. J Nucl Med 30:1636-1645.
80. Riva P, Franceschi G, Arista A and et al. (1997) Local application of radiolabeled monoclonal antibodies in the treatment of high grade malignant gliomas. A six-year clinical experience. Cancer 80:2733-2742.
81. Bigner DD, Brown MT, Friedman AH and et al. (1998) Iodine-131-labeled antitenascin monoclonal antibody 81C6 treatment of patients with recurrent malignant gliomas: Phase I trial results. J Clin Oncol 16:2202-2212.
82. Cokgor I, Akabani G, Kuan CT and et al. (2000) Phase trial results of iodine-131-labeled antitenascinmonoclonal antibody 81C6 treatment of patients with newly diagnosed malignant gliomas. J Clin Oncol 18:3862-3872.
83. 131I-labeled antitenascin monoclonal antibody 81C6 administered into surgically created resection cavities of patients with newly diagnosed malignant gliomas. J Clin Oncol 20:1389-1397.
84. Hall WA and Fodstad O (1992) Immunotoxins and central nervous system neoplasia. J Neurosurg 76:1-12.
85. Debinski W (2002) Local treatment of brain tumors with targeted chimera cytotoxic proteins. Cancer Investig 20:801-809.
86. 389EGF fusion protein therapy of refractory glioblastoma multiforme. Curr Pharm Biotechnol 4:39-49.
87. Pastan I, Chaudhary VK and Fitzgerald D (1992) Recombinant toxins as novel therapeutic agents. Ann Rev Biochem 61:331-354.
88. Laske DW, Youle RJ and Oldfield EH (1997) Tumor regression with regional distribution of the targeted toxin TF-CRM107 in patients with malignant brain tumors. Nature Med 3:1362-1368.
89. Weaver M and Laske DW (2003) Transferrin receptor ligand-targeted toxin conjugate (Tf-CRM107) for therapy of malignant gliomas. J Neuro Oncol 65:3-13.
90. Sampson JH, Akabani G, Archer GE and et al. (2003) Progress report of a phase I study of the intracerebral microinfusion of a recombinant chimeric protein composed of transforming growth factor (TGF)-α and a mutated form of the Pseudomonas exotoxin termed PE-38 (TP-38) for the treatment of malignant brain tumors. J Neuro Oncol 65:27-35.
91. Weber F, Asher A, Bucholz R et al. (2003) Safety, tolerability, and tumor response of IL4-Pseudomonas exotoxin (NBI-3001) in patients with recurrent malignant glioma. J Neuro Oncol 64:125-137.
92. Weingart J, Tatter S, Rosenfeld S et al. (2003) Intratumoral convection-enhanced delivery of IL13-PE38QQR cytotoxin for recurrent malignant glioma without planned resection: A phase I/II study. Neuro-Oncol 5:357.
93. Prados M, Kunwar S, Lang FF et al. (2005) Final results of phase I/II studies of IL13-PE38QQR administered intratumorally (IT) and/or peritumorally (PT) via convection-enhanced delivery (CED) in patients undergoing tumor resection for recurrent malignant glioma. Proc Am Soc Clin Oncol 23:115s.
94. Shin SU, Wu D, Ramanathan R, Pardridge WM and Morrison SL (1997) Functional and pharmacokinetic properties of antibody/avidin fusion proteins. J Immunol 158:4797-4804.
95. Friden PM, Walus LR, Musso GF, Taylor MA, Malfroy B and Starzyk RM (1991) Anti-transferrin receptor antibody and antibody-drug conjugates cross the blood-brain barrier. Proc Natl Acad Sci USA 88:4771-4775.
96. Pardridge WM, Buciak JL and Friden PM (1991) Selective transport of an anti-transferrin receptor antibody through the blood-brain barrier in vivo. J Pharmacol Exp Ther 259:66-70.
97. Coloma MJ, Lee HJ, Kurihara A et al. (2000) Transport across the primate bloodbrain barrier of a genetically engineered chimeric monoclonal antibody to the human insulin receptor. Pharm Res 17:266-274.